The Enhanced Games fit right in with the rest of 2026’s longevity vibes

<div data-chronoton-summary="

  • Drugs are the point: The inaugural Enhanced Games, held in Las Vegas this Sunday, openly encourages its 42 athletes to use performance-enhancing drugs — provided they’re FDA-approved and medically supervised — with $1 million on offer for world records broken.
  • FDA-approved doesn’t mean risk-free: Anabolic steroids, growth hormones, and other permitted substances carry serious health risks, including liver tumors, diabetes, and vision problems.
  • It fits the moment perfectly: From peptide clinics to optimized embryos, the Enhanced Games reflect a broader cultural obsession with pushing past human limits — one where just being human isn’t enough anymore

” data-chronoton-post-id=”1137753″ data-chronoton-expand-collapse=”1″ data-chronoton-analytics-enabled=”1″>

This Sunday, a group of 42 athletes will gather in Las Vegas to compete in a somewhat unusual sporting competition. Participants in the inaugural Enhanced Games are being encouraged to take performance-enhancing drugs. The goal is to “push the boundaries of human performance.”

The games’ organizers have said that competitors will only be taking substances that have been approved by the US Food and Drug Administration, and that they are all being medically monitored and supervised. But they have also said they expect to see world records broken—and are offering substantial prizes to athletes who succeed in doing so.

As you might expect, the event is generating a mix of curiosity, excitement, and condemnation from various quarters. To me, it feels like very much a reflection of where we are today—an era of peptide-crazed looksmaxxing in which consumers are being encouraged to get thinner than ever, optimize for longevity, and have their “best baby.” It’s 2026, and if you’re not enhancing, what are you even doing?

So, these games. They’ll feature competitions in four categories: swimming, track and field, weightlifting, and strongman (which also involves lifting weights). Many of the competitors already hold national and world records, and some are Olympic medalists. They’ve been paid a salary and will compete for prizes from a $25 million pot. The money has been a major draw for at least some of the athletes.

Another draw is the opportunity to openly experiment with drugs that might boost their performance. In the world of elite sport, every microsecond and every millimeter counts. Athletes—most of whom arguably have genetics on their side already—follow meticulous diet, training, and recovery protocols and wear specially designed gear that allows them to reach for those performance bests.

But within most sporting communities, there are limits. The World Anti-Doping Agency—an international outfit that fights the use of drugs in sports—maintains a lengthy list of “non-approved substances” that are banned in international sporting events. It features many anabolic steroids (which can build muscle), hormones (such as those that stimulate testosterone production or increase the ability of blood to carry oxygen), growth factors (which can stimulate muscle growth and repair, among other things), and more.

Some of these substances have been FDA approved to treat health disorders. And that means they can be used by participants in the Enhanced Games, according to the organization’s rules.

I’ll briefly point out the obvious here—just because a drug has been approved by the FDA doesn’t mean it’s totally safe for everyone and anyone. The risks associated with use of anabolic steroids, for example, include high blood pressure, acne, depression, and liver tumors. Growth hormone use can cause weak muscles, affect vision, and even lead to diabetes.

“Technological doping,” or using improved equipment to gain advantage, has also been supported by the games’ organizers. Last year, participating swimmer Kristian Gkolomeev was reported to have broken a record in a 50-meter freestyle time trial while wearing a polyurethane “super” swimsuit. Such suits have been banned for use in the Olympics since a slew of record-breaking performances in 2008 and 2009. Back then, the swimming governing body ruled that they gave athletes an unfair advantage. But hey, this is the Enhanced Games, where the word “unfair” seems to have a completely different meaning.

Can we expect more records to be broken on Sunday? Maybe. In addition to prize money for winning an event, any athlete who manages to beat a record stands to win up to $1 million, the sum also awarded to Gkolomeev last year following his time trial. But those performances won’t be recognized by official sporting bodies.

Plenty of concerns have been raised about these games. Some argue that they are unsafe and promote risky drug use. Others see them as a “clown show,” and a slap in the face to “clean” athletes who train hard without the use of prohibited drugs. World Athletics president Sebastian Coe has said that anyone who takes part is “moronic,” and World Aquatics, which oversees international competitions in water sports, has banned Enhanced Games participants from its events and activities.

But. The games—and the participating athletes—will still get a huge amount of attention. As a result, so will performance-enhancing drugs. Enhanced, the company behind the games, also runs an online store. There, you can buy a $52 T-shirt emblazoned with the message “I am Enhanced.”

There is also a range of prescription drugs on offer, including peptides “to support recovery, vitality, and longevity.” One of these is a growth hormone that the FDA approved in 1997 for the treatment of children with “growth failure.” The compounded version offered on the Enhanced website, which is not FDA approved, is marketed for longevity, supporting deep sleep and “overall wellness and vitality.” (“Marketed” is the key word here. The drug has, again, not been approved for that purpose.)

It all fits very well with the zeitgeist. Sure, we don’t yet have any drugs that are designed to extend human lifespan. But the search for anti-aging drugs is getting more attention—and funding—than ever. People, particularly women, are seemingly not allowed to visibly age anymore—we have filters and facelifts for that now. The idea that “death is wrong” is gaining acceptance.

And self-experimentation is rife. “Biohacking” was shortlisted for Collins Dictionary’s Word of the Year in 2025. Peptides are everywhere, despite all the unknowns surrounding their safety and effectiveness. So are longevity clinics, despite the fact that most are selling unproven treatments. US states like Montana are making it easier for people to get hold of unapproved “therapies.”

Companies are even offering would-be parents the option to choose the potential future children expected to live longest. Yep—you can supposedly optimize your embryos now, too.

In this climate, the Enhanced Games don’t feel so radical. They feel entirely fitting for our era of questionable optimization despite the risks —an era when, apparently, being human is no longer enough.

Google I/O showed how the path for AI-driven science is shifting

<div data-chronoton-summary="

  • Singularity rhetoric meets real-world tools: Google DeepMind CEO Demis Hassabis declared we’re in the “foothills of the singularity” — after showing off a hurricane forecasting tool. The gap between that grand vision and current successes captures a genuine tension inside AI science right now.
  • Specialized systems are losing the spotlight: Nobel Prize-winning AlphaFold transformed biology, but Google appears to be quietly shifting resources toward general-purpose AI agents — including having AlphaFold co-creator John Jumper work on AI coding.
  • Agentic AI is making real scientific moves: An OpenAI general reasoning model just disproved a significant mathematics conjecture, suggesting that AI doesn’t need to be purpose-built for science to meaningfully advance it.
  • Google is hedging its language, if not its bets: The company calls one of its agentic systems “AI Co-Scientist” rather than “AI Scientist” — a deliberate choice — but if Hassabis is right about where this is heading, that distinction may not hold for long.

” data-chronoton-post-id=”1137813″ data-chronoton-expand-collapse=”1″ data-chronoton-analytics-enabled=”1″>

During Tuesday’s Google I/O keynote, Demis Hassabis, the CEO of Google DeepMind, proclaimed that we are currently “standing in the foothills of the singularity.” It was a striking statement—the singularity is the theoretical future moment when AI rapidly exceeds human intelligence and dramatically transforms the world. But what struck me as I listened in the audience was the context in which he said those words. 

He was on stage to close out the session with a segment on scientific AI, the centerpiece of which was a video detailing how the company’s weather prediction software provided an advance alert about Hurricane Melissa’s catastrophic landfall in Jamaica last year—and potentially saved lives. If that software, called WeatherNext, helped anyone escape the storm or better fortify their home, that’s an enormous and meaningful achievement. But it’s hardly evidence of an impending singularity.

The juxtaposition of Hassabis’ lofty rhetoric with the real-world results of WeatherNext highlighted the tension between two very different approaches to AI for science. The first focuses on AI tools, like WeatherNext, that are designed and trained to solve specific scientific problems. The second is agentic, LLM-based systems that could one day execute cutting-edge research projects without human involvement.

This second vision powers a great deal of AI enthusiasm right now, including recent excitement around recursive self-improvement, or the idea that AI systems could eventually become the primary drivers of AI advancement—a process that would get faster and faster as the AI systems grow smarter. And agentic systems are now making real research contributions, sometimes with limited human guidance.

Just this week, Pushmeet Kohli, Google Cloud’s chief scientist, published a piece in a special AI and science issue of the journal Daedalus, writing: “We are moving toward AI that doesn’t just facilitate science but begins to do science.” With autonomous AI scientists on the horizon, it’s harder to justify massive efforts to develop super-specialized tools—even one like AlphaFold, for which DeepMind scientists won a Nobel Prize, or a potentially life-saving system like WeatherNext. It also heralds a far stranger future for science, in which humans and AI systems collaborate as peers—or AI even makes scientific progress on its own.

To be clear, Google does not appear to be abandoning its work on specialized AI for science tools. AlphaGenome and AlphaEarth Foundations, which are trained for genetics and Earth science applications respectively, were released last summer, and the newest version of WeatherNext came out in November.

What’s more, such tools remain extremely popular among scientists. Last year, for instance, Google reported that protein structure predictions from AlphaFold have been used by over three million researchers worldwide. And Isomorphic Labs, a Google subsidiary that aims to use AlphaFold and related technologies to develop new drugs, just raised a $2 billion Series B funding round.

But there are concrete signs of realignment, in both enthusiasm and resources. Last month, the Los Angeles Times reported that Google fellow John Jumper, who won the Nobel for AlphaFold, is now working on AI coding, not on science-specific AI tools. It’s not surprising that Google is assigning its best minds to the coding problem, as the company has recently taken a reputational hit because its coding tools don’t currently stand up to those offered by Anthropic and OpenAI. But it may also signal a prioritization of agentic science on Google’s part, as coding abilities are key to the success of some of those systems. 

Across the industry, agentic researcher systems are showing real potential. This week, OpenAI announced that one of their models had disproved an important mathematics conjecture—perhaps the most meaningful contribution that generative AI has made to mathematics so far, according to some mathematicians.

Importantly, the model used by OpenAI is not specialized for solving mathematical problems, or even for research; according to the company, it’s a general-purpose reasoning model in the vein of GPT-5.5. If general agents can make independent contributions to mathematical research, they might soon be able to do the same in science (though the fact that ideas in science must be verified experimentally makes it a tougher domain for AI).

Google is certainly devoting a lot of attention toward an agent-driven scientific future. The big scientific announcement at I/O was the new Gemini for Science package, which unites several of the company’s LLM-based scientific systems under one brand.

This includes the hypothesis-generating AI Co-Scientist and algorithm-optimizing AlphaEvolve, which are still not publicly available—but as Google is now allowing any researcher to apply for access to Gemini for Science, they may soon see wider adoption in the scientific community. Scientists who were involved in early testing are enthusiastic about their potential: Gary Peltz, a Stanford geneticist, compared using the AI Co-Scientist to “consulting the oracle of Delphi” in a Nature Medicine article.

Gemini for Science isn’t incompatible with specialized tools; to the contrary, agentic systems can be designed to call on such tools when they might be useful. And no agentic system can predict the structure that a protein will fold into without AlphaFold’s help (at least not yet). But the company seems to be shifting its public image—and at least some resources and personnel, such as Jumper—away from specifically developing those kinds of tools. Though it has only been five years since AlphaFold solved the protein-folding problem, both the technology and the discourse have quickly moved beyond that once-revolutionary achievement.

Google has been careful to position this new set of scientific agents as an accelerant for human scientists, rather than a replacement for them—the choice of the name AI Co-Scientist as opposed to AI Scientist, for instance, appears quite deliberate. Hassabis uses that same human-centric framing when he talks about changes in the landscape of scientific AI. “For the next decade or so, we should think about AI as this amazing tool to help scientists,” Hassabis said in an interview published in the Daedalus issue. “Beyond that timeframe, it is hard to say with any certainty, but perhaps these systems will become more like collaborators.”

But no one can be an effective scientific collaborator without also being a skilled scientist in their own right. And if Hassabis is anywhere near the mark when he talks about the “foothills of the singularity,” then AI scientists could eventually exceed the capabilities of their human counterparts.

In a discussion with the journalist Mike Allen at I/O, Hassabis spoke of how he was initially inspired to pursue AI when he observed how progress in physics had stagnated since the 1970s; he wondered whether the human mind had reached its limits in that domain, and if AI could help to overcome that barrier. Superhuman agentic scientists would certainly fit that bill. We might not ever get anywhere near there, but Google seems to be aiming itself toward that summit.

Tech researchers are suing the Trump administration over the future of online safety

<div data-chronoton-summary="

  • Researchers are fighting back: The Coalition for Independent Technology Research is suing the Trump administration over visa restrictions targeting foreign-born researchers who study content moderation and online safety, arguing the policy is unconstitutional and chills free speech.
  • A deliberately broad crackdown: The policy, announced by Secretary of State Marco Rubio, claims to target individuals that facilitate “foreign censorship.” But the lawsuit alleges that this is vague enough that anyone in fact-checking or online safety could theoretically face travel bans or deportation.
  • Real people, real consequences: As one example of the real consequences of chilling effects, online safety expert Eirliani Abdul Rahman left the US for Germany, describing the climate of government action and shifting tech company policies as untenable for her to continue her work safely or effectively
  • ,

  • The stakes go beyond researchers: The outcome could affect what the public learns about AI and social media risks; it was independent research quantifying the extent of Grok’s generation of millions of sexualized images of children that triggered government investigations worldwide.

” data-chronoton-post-id=”1137632″ data-chronoton-expand-collapse=”1″ data-chronoton-analytics-enabled=”1″>

Since its earliest days back in office, the Trump administration has been going after researchers who study and try to counter hate speech, harassment, propaganda, and disinformation online. 

Now, some of those researchers are fighting back. Last week their lawsuit—which could have global repercussions for online safety and free speech—made its first appearance in court

This fight started a year ago, when US Secretary of State Marco Rubio announced on X what he called a “visa restriction policy” against “foreign officials and other persons” who were “complicit in censoring Americans.” Since then, a handful of foreign officials and researchers have been barred from travel to the US, and in theory, anyone working in fact-checking or online trust and safety more broadly could face the same restrictions. 

Still, the exact implications of Rubio’s announcement are unclear—purposefully so, argues Carrie DeCell, a lawyer representing the researchers. “This policy is expansive and incredibly vague, and the chilling effects are correspondingly enormous,” DeCell said outside the courthouse in Washington, DC, on May 13.  

The case has been brought by the Coalition for Independent Technology Research (CITR), an advocacy organization for tech researchers. It is suing Rubio, former US secretary of homeland security Kristi Noem, and former US attorney general Pam Bondi and asking the court to strike down the policy as unconstitutional. In their complaint, the plaintiffs say the policy violates the speech and due process rights of foreign-born tech researchers and workers whose “work supports greater moderation of content on the [tech] platforms.”

CITR is represented by Columbia University’s Knight First Amendment Institute and the legal nonprofit Protect Democracy. DeCell, a senior staff attorney at the Knight Institute, tells MIT Technology Review that they’re in court because the Trump administration is effectively “using immigration law to punish people for expressing views that it disagrees with.” 


This story is part of MIT Technology Review’s “America Undone” series, examining how the foundations of US success in science and innovation are currently under threat. You can read the rest here.


Most immediately, the plaintiffs are asking the government to halt these visa restrictions while the case proceeds. Zachariah Lindsey, the assistant US attorney representing Rubio and the other defendants, argued in last week’s hearing that the government is not targeting speech but, rather, “conduct [that] is assisting or facilitating foreign government censorship of free speech.” At the end of the week, the government filed a motion to dismiss the case.

The judge has yet to rule on either motion, and his questions so far appeared to focus on parsing what (and who) is actually affected by the State Department’s announcements, as well as other procedural issues. 

The outcome of the case may ultimately affect how much the public knows about the risks of social media and AI, says Nicole Schneidman, head of Protect Democracy’s technology and data governance team. The workers bringing this suit, she says, “serve a really, really important function in educating the public, holding tech companies accountable, doing research on the ramifications that advanced technology has on our society.” 

“A political witch hunt”

CITR’s lawsuit is the latest salvo in a yearslong battle over how the internet should be moderated, and by whom—a question that has become increasingly political and entangled in allegations of censorship. 

For years, Trump and his allies have claimed to be victims of a vast conspiracy between government agencies, civil society groups, academics, and Big Tech platforms to specifically censor conservative voices online. According to this narrative, a so-called “censorship-industrial complex” helped the Biden administration subvert First Amendment protections on speech by allegedly outsourcing censorship to these groups.

The State Department claims Rubio was able to implement the immigration policy because the Immigration and Nationality Act authorizes him to “render inadmissible any alien whose entry into the United States ‘would have potentially serious adverse foreign policy consequences for the United States.’” Before the current Trump administration, the statute was rarely invoked, and when it was, it was typically with more limited, specific criteria, rather than its current application against anyone who has participated in alleged censorship—an action that has no legal definition. 

The administration first deployed the policy in July 2025, when Rubio issued a statement announcing the revocation of visas for Alexandre de Moraes, the lead justice on the Brazilian Supreme Federal Court, and “his allies on the court” who were involved in prosecuting Jair Bolsonaro, Brazil’s former president. The prosecution was a “political witch hunt,” said Rubio, calling it evidence of a “censorship complex so sweeping that it not only violates basic rights of Brazilians, but also … targets Americans.”

Then, in early December, the State Department issued instructions to embassies to reject H-1B visa applications from individuals who had worked specifically in fact-checking, online trust and safety, and mis- or disinformation research, as Reuters first reported. 

A few weeks later, on December 23, the agency announced visa restrictions for five Europeans whom it accused of censoring Americans. This included two CITR members: Imran Ahmed, founder and CEO of the Center for Countering Digital Hate, which documents hate speech on social media platforms, and Clare Melford, cofounder of the Global Disinformation Index, which ranks websites according to how often they publish hate speech and disinformation. Also banned were the former European Union commissioner Thierry Breton, a key architect of the European Union’s Digital Services Act (which the State Department has called “Orwellian” and an example of censorship), and Josephine Ballon and Anna-Lena von Hodenberg, co-CEOs of HateAid, a German nonprofit that fights online hate speech. 

Ahmed, who lives in the US with his American wife and child, quickly filed his own lawsuit to stave off deportation and halt the policy. A preliminary injunction preventing his detention and deportation is in place as the lawsuit continues. 

The Department of Homeland Security referred questions from MIT Technology Review to the State Department, which referred “specific questions” to the Department of Justice, while also writing that “the Trump Administration believes that aliens who are or were involved or complicit in censoring American citizens must face appropriate consequences. An American visa is a privilege not a right.” The Department of Justice did not respond to a request for comment. 

“A gut punch”

Now, more tech researchers are fighting back. 

CITR represents 500 individual and institutional members in 47 countries; 40 are based in the United States, including around 30 noncitizens. The organization argues that US-based tech researchers are experiencing a widespread chilling effect and are having to change or reframe what they’re studying so that it’s less explicitly (or less obviously) about content moderation or countering disinformation. Alternatively, some are leaving the US altogether, or making plans to do so, in order to safely carry out their work. 

CITR member Eirliani Abdul Rahman, a Singaporean online safety expert and a founding member of Twitter’s Trust and Safety Council, is one of these individuals. Her experience was included, though described anonymously, in CITR’s initial legal complaint. 

Back in December 2022, shortly after Elon Musk purchased Twitter, Abdul Rahman and two other Trust and Safety Council members publicly resigned. They spoke out against “red lines” the new owner had crossed, including his reinstatement of accounts that had previously been banned, and noted the marked increase in hate speech on the platform. 

Musk disbanded the council days later, but first he retweeted a post that tagged Abdul Rahman and the others and said: “You all belong in jail.” This led to a level of online harassment, doxxing, and death threats that she had never before experienced. “I was trained as an economist, and I could just see line graphs form in my head of the stochastic jump in what happened,” Abdul Rahman says, referring to the way the dangerous attention spiked after Musk effectively endorsed the other user’s provocation. 

This experience inspired her to pursue a new area of research: using quantitative methods to study and hopefully stop social media harassment “in real time,” she says. 

“The ones that are most harassed are people [who] have historically been marginalized,” she adds. “Most of us know about this already, like it’s intuitive. But until you quantify it, sometimes it’s just not seen and taken seriously.”   

But then Trump was reelected, making the work feel untenable. The US quickly became “a funding desert” for scientific research, she says, with federal support for any research perceived by conservatives to focus on mis/disinformation getting cut. At the same time, tech companies shifted their positions on content moderation to align with the president’s, meaning that her research would be unlikely to have any practical implications: “There’s simply no guardrails around social media anymore,” she says. 

Fast-forward to December 2025, and the travel bans on the five Europeans felt like “a gut punch to the stomach,” Abdul Rahman says. She and Ahmed had both testified earlier in the year before the UK Parliament on the role social media played in spreading false claims about the supposed Muslim identity of a murderer who had killed three British girls; this online activity contributed to violent anti-immigrant and Islamophobic riots across the country in the summer of 2024. 

The targeting of Ahmed and the other Europeans “was the last straw” for Abdul Rahman. Soon after, she left the US for a six-year fellowship in Germany aimed at supporting “international academic freedom”—coincidentally arriving in the country on the same day CITR filed its lawsuit. 

“My body just calmed down,” Abdul Rahman says of landing in Germany. “I didn’t wake up in the middle of the night … always wondering about the next executive order and how it pertained to my situation.”

Abdul Rahman believes this legal battle has implications that reach beyond CITR members and their families. It “pertains to all immigrants in the US to protect our First Amendment rights,” she says.

Additionally, whether fact-checkers, online trust and safety workers, and tech researchers can continue to do their work has a broader impact on anyone who uses the internet. 

Earlier this year, for example, Ahmed’s Center for Countering Digital Hate published widely cited research that Grok’s image-editing feature had generated an estimated 3 million sexualized images, including 23,000 images of children, in an 11-day period. This led to government investigations, lawsuits, and even temporary bans for Grok’s parent company, xAI, across the United States and world. 

“The threats have really sharpened”

MIT Technology Review has reported extensively on this right-wing war on supposed censorship; one of our stories revealing that State Department leadership requested communications records from a now-shuttered office focused on countering foreign disinformation has been included as an exhibit in the CITR lawsuit. This request sought insight into communications with a slew of individuals some far-right activists allege are involved in the “censorship-industrial complex,” including journalists, the German foreign minister, and numerous researchers studying disinformation and hate speech (including Medford, Ahmed, and their organizations).

DeCell tells us that over the past year and a half, there have been more lawsuits against the Trump administration regarding free speech—because “the threats have really sharpened,” she says.

Last year, the Knight Institute sued Rubio on behalf of of university faculty and students who have been arrested, detained, and deported for their pro-Palestinian speech; this past January, a judge ruled that the administration’s deportation policy was unconstitutional. The risk to free speech rights is “palpable” when the government “decides to target people specifically with the threat of rounding them off the streets, throwing them into a detention center, and then potentially deporting them from this country,” DeCell says. 

Though Abdul Rahman is safely abroad for now, she says she’s watching the CITR lawsuit closely. Ultimately, she says, she believes it will determine whether researchers will be able to continue to do their work, “which is to take social media platforms to account,” she says—“making sure there’s actual accountability and independent oversight is critical to protecting our democracies.” 

Anthropic’s Code with Claude showed off coding’s future—whether you like it or not

The vibes were strong at Code with Claude, Anthropic’s two-day event for software developers in London that kicked off on May 19, the same day as Google’s I/O in Palo Alto. (A coincidence, not a flex, Anthropic staffers assured me.)

“Who here has shipped a pull request in the last week that was completely written by Claude?” Jeremy Hadfield, an engineer at Anthropic, asked from the main stage. Almost half the people in the packed room—many sitting with laptops on their knees, coding or prompting as they watched the talks—raised their hands.

Pull requests are fixes or updates to existing software that are submitted for review before they go live. They are the bread and butter of software development, the chunks of code that most professional developers spend their lives writing—or did until now.

“Who here has shipped a pull request that was completely written by Claude where they did not read the code at all?” Hadfield asked next. Nervous laughter. Most of the hands stayed up.

It’s not news that LLM-powered tools like Anthropic’s Claude Code and OpenAI’s Codex have upended the way software gets made. Top tech companies now like to boast of how little code their developers write by hand. (“Most software at Anthropic is now written by Claude,” Hadfield said. “Claude has written most of the code in Claude Code.”) OpenAI, Google, and Microsoft make similar claims. Many others wish they could.

Even so, it is striking how normal this new paradigm already seems, and how fast it has set in. This was the second year that Anthropic has put on developer events, which also run in San Francisco and Tokyo. This time last year, the company had just released Claude 4. It could code, kind of. But with Anthropic’s latest string of updates—especially Claude 4.6 and then 4.7, released in February and April—Claude Code is a tool that more and more developers seem happy to hand their work off to.   

An 8-bit character with a chef's hat in a pixel kitchen flips food in a fry pan over a pixel stove
Let Claude cook.
ANTHROPIC (GRAPHIC) / WILL DOUGLAS HEAVEN (PHOTO)

Anthropic says its goal is to push automation as far as it will go. Instead of using AI to generate code and then having humans clean it up and fix the mistakes, it wants Claude to check and correct its own work. “The default isn’t ‘I’m going to prompt Claude’—the default is now ‘I’m going to have Claude prompt itself,’” Boris Cherny, who heads Claude Code, said in the opening keynote.

If all goes well, human developers shouldn’t even see the error messages when something doesn’t work. That will all be handled by Claude, which will test and tweak, test and tweak, until everything runs as it should. As Ravi Trivedi, an engineer at Anthropic, put it in another talk: “The key principle is getting out of Claude’s way. We like to say: ‘Let it cook.’”

Trivedi presented a new feature in Claude Code, announced two weeks ago, which Anthropic calls dreaming. Claude Code agents write notes to themselves, recording and saving useful information about specific tasks. When another coding agent later starts to work on the same code, it can use the notes to get up to speed faster and learn from any errors that previous agents may have made.

Dreaming is a system that Claude Code uses to read through all these notes and consolidate the information they contain, spotting patterns and common issues across different tasks. In theory, dreaming should help Claude Code learn about a particular code base and get better and better at working on it.

Success stories

Code with Claude is an event aimed at developers. As well as product showcases and hands-on workshops from Anthropic, there were how-tos from a range of companies that had reshaped their software development teams around Claude Code, including Spotify and Delivery Hero as well as Lovable, Base44, and Monday.com—three startups vibe-coding apps that help people vibe-code apps.

There were no signs of unease at Code with Claude. Everybody I met wanted in.

And yet outside the conference there have been a number of reports that many coders are starting to question this bright new future. Some gripe in online forums like Reddit and Hacker News that AI coding tools are being pushed by managers chasing productivity gains, when in practice the technology makes software development harder because of all the extra code developers now have to review. “The only people I’ve heard saying that generated code is fine are those who don’t read it,” a user called pron posted on Hacker News last week. 

Others claim that their coding abilities have fallen off as they hand more tasks to AI. And researchers have warned that AI tools can produce unsafe code that will make software more vulnerable to attacks.  

I sat down with Claude engineering lead Katelyn Lesse and Claude product lead Angela Jiang and asked them what they made of the concerns that a sudden flood of code generated (and shipped) without proper human oversight was kicking serious security and maintenance problems down the road.

“All of the old software development best practices still apply. They’ve applied this entire time,” said Lesse. “I think there are a lot of people and teams that may have lost sight of them in this moment.” 

And yet as Anthropic and others push for greater automation and tools like Claude Code improve, the temptation increases to offload more and more tasks, including oversight. Lesse told me that some of the technical managers at Anthropic are exhausted by keeping up with all the code their teams now produce. “Part of things happening so much more quickly is just managing your time,” she said.

“I think that right now Claude is probably as good as a midlevel engineer at writing code,” she added. You still need expert engineers to design a system and troubleshoot harder problems, she said, “But over time we want Claude to get better and better at all different types of engineering.”

Jiang agreed: “I think the absolute end state we’re trying to get to is Claude basically being able to build itself.”

Green steel startup Boston Metal is doubling down on critical metals

<div data-chronoton-summary="

  • Boston Metal has raised $75 million after a rough stretch that included an industrial incident and laying off 71 employees earlier this year.
  • The company is shifting focus to critical metals like niobium, tantalum, and chromium, which command higher prices and could help prove its technology before returning to steel.
  • Its commercial facility in Brazil, delayed by an electrolyte leak in January, is now being repaired and is expected to start up in September 2026.
  • The round includes support from Tata Steel, one of the world’s largest steelmakers, bringing Boston Metal’s total funding to over $500 million.

” data-chronoton-post-id=”1137523″ data-chronoton-expand-collapse=”1″ data-chronoton-analytics-enabled=”1″>

The startup Boston Metal has raised a $75 million funding round to produce critical metals, MIT Technology Review can exclusively report.  

The company has been known largely for its efforts to clean up steel production, an industry that’s responsible for about 8% of global greenhouse emissions today. With the additional money, the new focus could help it survive at a time when support for industrial decarbonization has been waning in the US.

In addition to steel, Boston Metal has also worked to use its technology with other metals, and a subsidiary (Boston Metal do Brasil) is setting up a commercial facility in Brazil to produce niobium, tantalum, and tin. The funding will help support that facility’s operation as well as future efforts to produce critical metals like vanadium, nickel, and chromium, says CEO Tadeu Carneiro. The funding comes after the company faced cash-flow problems following an industrial accident at the Brazil facility earlier this year.

Boston Metal’s core technology is called molten oxide electrolysis (MOE). It involves running electric current through a reactor filled with ore dissolved in a molten electrolyte. The electricity heats everything up to about 1,600 °C (3,000 °F) and drives chemical reactions that separate the desired metal (or metals) from the ore. The metal gathers at the bottom of the reactor, where it can be siphoned off.

In early 2025, Boston Metal completed the largest run of its pilot industrial cell in Woburn, Massachusetts, producing about a ton of steel.

But the focus is currently on making other metals, which are more valuable and can command a higher price. The company’s Brazilian subsidiary is working to test and start up an industrial-scale plant that takes in a low-grade material and makes a mixture of critical metals. Niobium, for example, is used in some steel alloys, as well as in alloys used to make jet engines and the superconducting magnets of MRI scanners. Tantalum is used in aerospace applications like rocket nozzles and turbine blades, as well as medical devices and electronics.

Construction on the Brazil plant kicked off in 2024 and took about 18 months, but the company ran into some challenges that delayed official startup.

In January there was an issue with the plant’s refractory system, the equipment that insulates the reactor and prevents corrosion. That caused electrolyte to leak. Operators shut down the system and removed the metal, and there weren’t any injuries or environmental issues, Carneiro says.

But the leak did interfere with the timeline for the plant’s opening, which meant the company missed a milestone and lost out on funding that had been committed. It restructured and laid off 71 employees in April.

This new funding will help support the plant moving forward. “Because of this delay, we had a big stress in our cash flow, so the investors came very strong to support us,” Carneiro says. Boston Metal is repairing the facility in Brazil now, and it should be ready to start up in September 2026, he adds.  

The funding will also help support other critical metals projects, Carneiro says. The company plans to eventually deploy a US plant to produce chromium, a metal the country imports nearly all its supply of today. 

Boston Metal has now raised over $500 million in total. The latest round of funding includes support from existing investors and from the massive Indian steel company Tata Steel Unlimited.

Making a higher-value critical metal now could help Boston Metal prove its technology and pave the way for future steel projects, says Seaver Wang, director of climate and energy at the Breakthrough Institute. “Nobody wants to pay a green premium for steel—hence niobium,” he adds.

Colossal Biosciences is growing chickens in a 3D-printed artificial eggshell

<div data-chronoton-summary="

  • Artificial eggshell, not artificial egg: Colossal Biosciences has grown baby chicks inside 3D-printed plastic containers coated with a silicone-based membrane that mimics an eggshell’s oxygen exchange — a meaningful step, but scientists say the company is overselling it.
  • The moa is one target: Colossal’s goal is resurrecting the giant moa, a 12-foot flightless bird hunted to extinction — which would require genetically rewriting thousands of DNA letters and scaling up the artificial eggs to the size of a salad spinner.
  • Scientists are skeptical: Researchers have been growing birds in artificial containers since 1998 and say Colossal’s claims of a first-ever breakthrough are overblown — a familiar pattern for a company that last year also faced widespread rejection of its “dire wolf” resurrection claim.

” data-chronoton-post-id=”1137471″ data-chronoton-expand-collapse=”1″ data-chronoton-analytics-enabled=”1″>

The baby chicks were shifting and starting to pip—or trying to hatch. But not from an egg. 

Instead, these chickens were growing inside transparent 3D-printed plastic cups at the Dallas headquarters of Colossal Biosciences.

The biotech company today claimed it has developed a “fully artificial egg” as part of its effort to resurrect extinct avian species, including birds like the dodo and the giant moa.

But “artificial eggshell” would probably be a better description for the invention. It’s an oval-shaped printed lattice, coated inside with a special silicone-based membrane that lets in oxygen, just as a real eggshell does. 

To generate birds, Colossal took recently laid chicken eggs and carefully poured their contents into the artificial shells, where they continued growing. A window on top lets researchers peek inside.  

“To see them all moving around in their artificial eggs was absolutely mind blowing,” says Andrew Pask, the company’s chief biology officer. “You really feel you can grow life outside of the womb.”

Colossal was founded in 2021 with plans to use gene editing and reproductive technology to restore extinct species, including the woolly mammoth. It’s since raised more than $800 million toward what it now terms the “scalable and controllable” creation of animals.

According to Pask, the egg technology could help conserve at-risk bird species. It could also play a role in a project to re-create the extinct giant moa, a flightless 12-foot-tall bird that once lived in New Zealand and laid four-liter eggs, larger than those of any living bird.

But Colossal may be able build one that’s big enough. The company provided a photograph of a prototype 3D-printed egg so large that staff have started to call it the “salad spinner.”

The moa went extinct after canoes carrying the ancestors of the Maori arrived on New Zealand’s South Island about 750 years ago. Archeological sites showcase the birds’ bones alongside stone cutting tools—clear evidence that they were hunted.

To be clear—Colossal isn’t close to re-creating the moa. Before that could happen, scientists would need to study DNA data from old moa bones and insert thousands of genetic changes into the genome of an existing bird, something that’s still technically difficult to do—with or without an artificial egg.

artificial womb for chicken embryos

COLOSSAL BIOSCIENCES

Some scientists also think Colossal is taking too much credit for its artificial eggshell, which it announced in a thundering YouTube video intoning that the company has solved the “impossible question of which came first, the chicken or the egg.”

The video is pure Hollywood—it’s meant to be funny and exciting. But Colossal has a habit of antagonizing scientists by making false and exaggerated claims. Last year, for instance, the company said it had re-created the extinct dire wolf—a claim widely rejected by experts. 

This time, Colossal’s fluffed-up assertion of having created the “first-ever shell-less incubation system” is what’s raising hackles among the small flock of scientists who’ve been working on the technology for years. 

“Clearly an overstatement,” says Katsuya Obara, at the University of Tsukuba in Japan, who in 2024 hatched chickens from beneath transparent plastic film. “The technology here is essentially a modification of existing methods.”

In fact, Obara notes, growing birds in artificial containers goes all the way back to 1998, when another Japanese group managed to do it with quail.

What may be an advance by Colossal is the special membrane, which lets the embryo access more oxygen. Previous systems required scientists to supplement the gas—something that may not have been good for the chicks, as often some of them would fail to hatch. 

The work on the artificial eggshell was carried out in Dallas by Colossal’s exogenous development team, or Exo Dev. That group is also trying to develop artificial wombs for mammals, starting with marsupials.

“We’re looking at every single facet of what’s happening during a mammalian pregnancy to unpack exactly how we then go about recapitulating that,” says Pask.

For that team, an artificial eggshell is a relatively quick and easy technical win. That’s because chickens are already an example of ex utero development. After an egg is laid, a small embryo sitting on top of the yolk starts growing, drawing nutrients from the yolk, the white, and even the shell, which provides calcium. (Colossal says it has to add ground-up calcium to the artificial eggs.)

looking down into the artificial egg shell to see a developing chick embryo and its vascular structure

COLOSSAL BIOSCIENCES

In order to create a moa, Colossal will have to genetically alter another type of bird, changing potentially thousands of DNA letters. But so far, chickens are the only bird species that can be genetically engineered. And that’s via a tricky process of editing stem cells that produce egg and sperm. Scientists have to add or delete DNA letters from these cells and then inject them back into an egg. The resulting bird will carry the genetic changes in its gonads—and then be able to pass them on. 

Pask says Colossal’s idea is that it could modify avian stem cells enough to produce moa-like sperm or eggs. But then you might have the odd situation of a chicken laying an egg with a moa embryo inside it. “You would have chickens making moa egg and moa sperm. But it’s still a chicken egg,” he says.

Helen Sang, a professor emeritus at the Roslin Institute in the United Kingdom, says she’s not sure a moa embryo could survive on the yolk of a chicken egg, given evolutionary differences. “There are significant challenges to overcome to grow an embryo of a different species in artificial eggs,” says Sang.

Just one of those is the huge size discrepancy. The amount of yolk in a chicken egg would hardly be enough to support the much larger moa chick. Yet Pask says that is exactly where the artificial egg will come in handy.

He says it may be possible to use a fine needle to slowly “put 50 yolks together to make that yolk mass much larger.”

“The chicken egg isn’t going to be big enough to support the growth of the moa through to term, to when it would normally hatch, but that’s when you could then take that egg, put it into the artificial egg environment, and then scale it up in size,” he says.

So far, Pask says, the artificial egg is working well for chickens—almost too well. “We hatched 26 chickens and then [our CEO] asked us to put the brakes on. We have too many chickens running around.”

A plan to make drugs in orbit is going commercial

<div data-chronoton-summary="

  • A big deal: Varda Space Industries says it has signed a pharmaceutical company as a commercial customer, marking what could be a landmark moment for in-orbit manufacturing.
  • Space as a lab: The bet is that microgravity causes drug molecules to crystallize into atomic arrangements impossible on Earth, potentially unlocking new versions of existing medicines.
  • Economics favor drugs: At $7,000 per kilogram to reach orbit, space manufacturing is impractical for most industries — but blockbuster drugs can be worth over $100 million per kilogram, making them a rare exception to the brutal math of rocket launches.
  • Still more experiment than factory: Despite the excitement, no product has ever been manufactured in space, brought back, and sold on Earth.

” data-chronoton-post-id=”1137153″ data-chronoton-expand-collapse=”1″ data-chronoton-analytics-enabled=”1″>

Varda Space Industries, a startup that’s been pitching its ability to perform drug experiments in space, says it has signed up the pharmaceutical company United Therapeutics in what may be remembered as a notable step toward in-orbit manufacturing.

The idea of building things in outer space for use on Earth has so far been explored mostly on board the International Space Station, and only in small-scale experiments backed by governments.

But Varda, based in El Segundo, California, is now telling drug companies it has a practical, and repeatable, way to produce novel molecules in microgravity. 

“This is the first commercial path to products made in space,” says Michael Reilly, Varda’s chief strategy officer.

The scientific idea is that chemical mixtures have different properties under weightless conditions. For instance, water will hang together in a wiggly sphere, since without gravity, surface tension is the strongest force present.

The plan is to launch versions of United Therapeutics’ drugs into orbit, where they can be allowed to form solid crystals. The hope is that in microgravity, they’ll take on atomic arrangements not seen on Earth, possibly leading to new versions with improved stability or other valuable properties.

United is led by CEO Martine Rothblatt, who worked on early telecommunications satellites. Since then, she’s built a multibillion-dollar health franchise with a succession of drugs to treat a lung disease called pulmonary arterial hypertension, which her daughter suffers from, and a subsidiary developing genetically modified pigs as a source of organs for transplantation.

Rothblatt says space could be the next step if orbital conditions permit United to identify “even more amazing” versions of its drugs.

Space to reformulate

Pharmaceutical companies often try to keep their blockbuster franchises alive by creating improved versions of drugs or reformulating them—for example, making the switch from a pill to an inhaled version, as United has done with some of its products. Doing so can keep imitators at bay and create extra decades of patent protection.

Assisting drugmakers are specialist companies, such as Halozyme and MannKind, that earn profits by helping to reformulate other companies’ drugs, often taking a royalty on future sales.

That’s the business Varda has been trying to break into—by using excursions into space instead of nebulizers, patches, or nanoparticles. The company was formed in 2021 by Delian Asparouhov, a partner at Peter Thiel’s Founders Fund, along with Will Bruey, a former avionics engineer with Elon Musk’s SpaceX who is now Varda’s CEO.

The pair’s bet is that space manufacturing will become viable once rocket launches become frequent enough—and cheap enough—to support a business model in which raw materials are sent into orbit, processed, and then returned to Earth in a new form.

And that’s starting to happen. To get into space, Varda has been purchasing rides from SpaceX—which now launches a rocket every two or three days, usually a reusable Falcon 9. 

Those rockets have a nose cone, or payload fairing, about the size of a moving truck that gets filled with satellites or instruments, which are then released into orbit.

Starting in 2023, Varda began sending up small satellites that have a boulder-size capsule attached. The capsule contains equipment to carry out experiments, and it can detach and fall back to Earth, entering the atmosphere at a speed of around Mach 25 before slowing via air resistance and eventually drifting to land with a parachute. (Varda lands its craft in the Australian outback.)

That speedy reentry has also drawn interest from the US military, including the Air Force, which has paid Varda to fly instruments and take measurements relevant to hypersonic missile technology. Of the six craft Varda has paid to put into orbit so far, half have been dedicated to military research and half carried drug-related demonstrations. 

At Varda, such “dual use” of technology is accepted as part of being in the space business, which remains reliant on government support. The company’s founders say Varda may be the only company that employs hypersonic engineers and pharmaceutical chemists under the same roof.

At Varda’s headquarters, drug samples are loaded into a spinning arm that creates extra-high g-forces. While that’s the opposite of microgravity, increased weight can provide clues into whether a drug will act differently under new conditions.
COURTESY VARDA

Launching industries

Actual space manufacturing still remains mostly an aspirational project. In 2021, Jeff Bezos, after his first trip aloft in a rocket, suggested that polluting industries should be moved beyond the atmosphere. “We need to take all heavy industry, all polluting industry, and move it into space. And keep Earth as this beautiful gem of a planet that it is,” he told MSNBC.

Weight is the big obstacle to such dreams. It still costs around $7,000 to launch a single kilogram of payload into orbit, which makes it impractical to, say, send cotton into space to be dyed there, or even to launch the acids and solvents needed to make a semiconductor chip.

But drugs may be among the few exceptions to this economic rule, since pound for pound, they can be as valuable as rare radioactive isotopes and fine-cut diamonds.

For instance, just one kilogram of the weight-loss drug Ozempic is worth more than $100 million at retail. (The reason your Ozempic bill is only $1,000 a month is that minute quantities of the active ingredient are present in the shots.)

That’s why Varda thinks it may eventually be able to manufacture drugs in orbit. However, its effort with United is more of a flying experiment to learn whether the company’s lung medicines will crystallize differently in microgravity.  

The terms of the deal between Varda and United aren’t public, and the companies haven’t said which specific drugs the collaboration will study. But Rothblatt did confirm that United is paying Varda to help it identify new crystal forms of its drugs (also called polymorphs), which it hopes could have improved properties.

“One has to do the experiment to find out if that is so. The first part of the experiment is to see what polymorphs of these molecules can be made without the influence of gravity,” she says. “Then, once we have those polymorphs, we will test them.” 

There is good evidence that crystals form differently in space. For instance, in 2017 the pharmaceutical giant Merck sent samples of its cancer immunotherapy drug Keytruda to the International Space Station, where it was found to form crystals of a single size. On Earth, the drug tended to form two different sizes at once.

That experiment offered clues for how to formulate the drug as a shot instead of administering it intravenously. Still, when Merck introduced a Keytruda injection last year, it ended up using a different approach. That means there’s still no straight-line connection between orbital discoveries and any drug here on Earth. Actual space factories are another step further from reality. 

“We’ve been learning from space for years, but I can’t name anything manufactured in space, brought down to Earth, and sold,” says Reilly. “So that is a first—or it will be a first.”

Reilly says that Varda anticipates launching United Therapeutics’ drugs into orbit sometime early next year. 

What’s next for IVF

<div data-chronoton-summary="

  • Helping embryos stick: Even healthy-looking embryos only implant 40–60% of the time. Researchers in Spain are trialing a device that physically injects embryos directly into the uterine lining at the press of a button.
  • AI and robots are taking over the lab: Automated systems can now select sperm, fertilize eggs, and culture embryos without human hands. At least 19 children have already been born through fully automated IVF.
  • Genetic testing is getting complicated: Standard embryo screening helps reduce miscarriage, but newer tests claiming to predict IQ or height are gaining ground in the US—and making many fertility doctors deeply uncomfortable.
  • Gene editing is quietly creeping back: Years after He Jiankui went to prison for editing human embryos, startups are revisiting CRISPR as a way to prevent serious inherited disease—raising hopes, and familiar fears about a slippery slope.

” data-chronoton-post-id=”1136946″ data-chronoton-expand-collapse=”1″ data-chronoton-analytics-enabled=”1″>

MIT Technology Review’s What’s Next series looks across industries, trends, and technologies to give you a first look at the future. You can read the rest of them here.

Forty-eight years ago this July, Louise Joy Brown became the world’s first person born with the help of in vitro fertilization. Millions more IVF babies have entered the world since then. And that’s partly thanks to advances in technology that have made IVF safer and more effective.

But it’s still not perfect. The process can be slow, painful, and expensive—and that’s for the lucky people who are able to access it in the first place. And by at least one measure, IVF success rates have been declining in recent years.

Reproduction is complex, and there’s a lot that embryologists and gynecologists still don’t know and can’t control. They don’t know why many healthy-looking embryos don’t “stick” in the uterus, for example. They don’t always have an explanation for why their patients can’t get pregnant. And they can’t always account for vast differences in IVF success rates between individuals and between fertility clinics.

Scientists are working on all those questions and more. They’re wrestling with complex ethical questions about how new genetic tools will be used to analyze or even alter embryos. Meanwhile, technologies designed to standardize treatment, eliminate human error, boost success rates, and make IVF more accessible are already beginning to usher in a new era for assisted reproduction—one aided by AI and robots.

1. Helping embryos stick

Some of those technologies are being developed at the Carlos Simon Foundation in Valencia, Spain. When I visited in March, researchers gave me a tour of the labs and showed me a device that had been used to keep a human uterus alive outside the body for the first time.

While some members of the team dream of building artificial uteruses that might one day be able to carry a fetus to term, they first want to use such devices to learn more about implantation—the moment at which a fertilized egg makes contact with the lining of the uterus, burrows inside, and essentially “hatches,” triggering the start of a pregnancy.

Despite decades of advances in IVF, that process is still poorly understood. Even healthy-looking embryos stick no more than 40% to 60% of the time.

In IVF techniques used today, clinics can create early-stage embryos and wait until the uterus is deemed most receptive, but once they insert the embryo into the uterus, it’s on its own. Xavier Santamaria, senior clinical scientist at the Carlos Simon Foundation, and his colleagues are trialing a different approach. They’ve developed a device that, at the press of a button, injects the embryo into the uterine lining.

Scientists in Valencia showcase Transfer Direct.

JESS HAMZELOU / MITTR

In a demonstration I watched with a prototype, Santamaria picked up his speculum and turned to face the vaginal opening of his “patient,” which in this case was just a model of the real thing—a plastic bottom with labia, a vagina, a uterus, and ovaries, two short stumps representing what would normally be a pair of legs held in stirrups.

He hunched over and peered inside. “Embryo,” he called. His colleague Maria Pardo, an embryologist, passed him a thin needle containing a mouse embryo she had recently collected from a petri dish.

Santamaria’s device allows for the embryo-containing needle to be connected to a delivery tube. This tube also has a camera, a light, and a sensor that lets the doctor know when the needle reaches the uterine lining. Once it has been fed into the uterus, the gynecologist can see the inside of the organ and direct the tube to the lining.

Scientists in Valencia showcase Transfer Direct.

JESS HAMZELOU / MITTR

“When everything is ready, you just press the button,” Santamaria said as he activated it using a foot pedal, allowing the embryo to be injected. “There it goes.”

The team has just started a trial of the device; so far, fewer than 10 women have undergone the procedure, and none of those have become pregnant. But foundation director Carlos Simon is hopeful, noting that the inventors of IVF had to perform over 160 cycles before Louise Brown was born (between 1969 and 1978, that team performed 457 cycles in 250 people, resulting in only two live births). “The trial is ongoing,” he says.

2. Picking the “best” eggs, sperm, and embryos

One long-running challenge of IVF has been selection. Say you manage to collect 10 eggs from one partner and a decent-looking semen sample from the other. How do you choose which cells to use? The same question comes up once the resulting embryos have been cultured in a dish for a few days: Which should you transfer to the uterus?

Traditionally, these judgments have been made by eye. Embryologists literally pick the ones that look the best in terms of their shape or, in the case of sperm, how they move. But scientists have been working on alternatives. And over the last decade or so, many have turned to genetic testing to hint at which embryos have the best chances of creating a healthy baby.

The most commonly used test is called PGT-A, which stands for preimplantation genetic testing for aneuploidy. Aneuploidy essentially means having an “incorrect” number of chromosomes, and it is thought that embryos with such characteristics are more likely to be lost through miscarriage or potentially develop into babies with genetic conditions.

Once embryologists have created embryos in the lab, they can pinch off a few cells and test them for aneuploidies. The tests are especially beneficial for women over the age of 38, says Alan Penzias, a reproductive endocrinologist at Boston IVF. “You start to see an improvement: more babies and fewer miscarriages,” he says. The tests can shorten the time to pregnancy.

This type of genetic testing is possible thanks to multiple advances in technology—not just in genomics, but also in the ability to keep embryos alive in a dish for five to six days and the technique of freezing embryos while the cells undergo testing and thawing them once the results are in. And it has become hugely popular—some clinics do PGT-A tests on all their embryos.

But PGT-A won’t give you a perfect readout of a future baby’s genetics, says Sonia Gayete-Lafuente, a reproductive endocrinologist at the Center for Human Reproduction in New York City. And some of the abnormalities might be able to self-correct with time. Gayete-Lafuente and her colleagues have transferred some of those “abnormal” embryos into patients’ uteruses and seen them develop into perfectly healthy children, she says.

Other forms of PGT are even more controversial. PGT-P tests are designed to predict an embryo’s chances of developing complex traits that rely on multiple genes, including medical disorders but also physical characteristics like height or cognitive factors like IQ. These tests are new, and they are illegal in some countries, including the UK. But they are gaining ground in the US. Nucleus Genomics—a company that invites customers to “have [their] best baby”—promises to predict traits running the gamut from eye color and intelligence to left-handedness and risk of Alzheimer’s.

When I asked IVF practitioners how they might respond if a patient asked for this service, most dodged the question and told me there’s not enough evidence that any of these tests actually work. They also cautioned that selecting for one trait might inadvertently introduce new risks. None seemed especially keen on the idea of using genetic testing for anything other than preventing serious disease.

3. Speeding things up with AI

Some seemed more excited about the potential for AI. After all, AI tools are generally good at recognizing patterns. Many researchers have attempted to train tools to spot healthy sperm, eggs, and embryos.

And they’ve had some success. A team at Columbia University Medical Center in New York has developed a device that uses AI to examine semen samples from men who have only tiny numbers of healthy sperm. An embryologist might struggle to find a single healthy sperm in such a sample. But the Sperm Tracking and Recovery (STAR) system can analyze over a million microscope images in an hour. It has already been used to create healthy embryos. The team behind the work announced the first pregnancy resulting from the treatment in November last year.

Other teams are using AI tools to advance IVF in more dramatic ways. Around a decade ago, a reproductive endocrinologist named Alejandro Chavez-Badiola began developing an AI tool trained to rank embryos, another to rank eggs, and another to select sperm. He recalls being struck by a realization that these tools were “the brains that have the potential to drive robots in the future,” he says.

4. Using robots to standardize IVF

In the early 2020s, Chavez-Badiola and his colleagues decided to combine technologies and develop an automated system for IVF. In theory, a robotic system loaded up with AI tools could undertake most of the steps required in the IVF process: selecting the eggs and sperm, fertilizing eggs to create embryos, culturing those embryos in a dish, and selecting the “best” one for transfer. Such a system could “do everything in a standard way” without ever getting tired, he says.

Chavez-Badiola, who is now founder and chief medical officer at Conceivable, started building prototypes by motorizing regular IVF equipment and connecting it to computers. He and his colleagues started testing their system with animal cells before eventually moving on to human ones. “We were able to prove that integrating robots to automate different steps in IVF is doable,” he says.

The device is now being used to prepare sperm and eggs and create embryos. At least 19 children have been born following the automated IVF. It is early days, but Chavez-Badiola is hoping that future iterations of the machine could each process thousands of IVF cycles in a year, potentially making the procedure more affordable and accessible.

Many in the field are excited about the potential for automated devices like Conceivable’s. “This is all time saved for the embryologists,” says Laura Rienzi, a clinical embryologist and scientific director of the IVIRMA network of fertility centers in Italy. She also hopes it will help standardize IVF treatments. “Automation [will allow for] every patient to be treated in the same way in every single lab in the world,” she says.

5. Controversial edits are on the table

There’s a catch, however: All these technologies rely on the availability of at least some healthy sperm, eggs, and embryos at the outset. Embryologists and IVF patients have to work with what they’ve got. And sometimes, what they’ve got won’t result in a healthy baby. 

That’s why some scientists are proposing a controversial idea: using gene-editing technologies like CRISPR to tinker with the genome of an IVF embryo before it is implanted. The biophysicist He Jiankui infamously took this approach to create embryos that resulted in the births of three children in the late 2010s. He was widely condemned by the scientific community and ultimately spent three years in a Chinese prison

His former romantic partner Cathy Tie, who now leads startup Origin Genomics, is pursuing the technology as a potential way to prevent serious disease in children. At a recent event held at the Hastings Center for Bioethics, Tie made the case for using embryo editing to prevent diseases like cystic fibrosis, Huntington’s, and sickle-cell.

It won’t be straightforward from a technical, legal, or ethical perspective. Diseases that are known to be caused by single-gene mutations are good first candidates, but as the Center for Human Reproduction’s Gayete-Lafuente points out, most diseases are much more complicated than that. “I wish we could understand the genetic basis of every disease to be able to prevent it,” she says. So far, we can’t. Besides, most diseases can be influenced by our diets, behaviors, and environments as well as our genes.

As things stand, no one knows if editing a human embryo to eliminate the risk of one disease might increase a future child’s risk of some other disorder. And some scientists worry that such edits might be a slippery slope to genetic enhancement or eugenics.

Rienzi hopes that the technology might be developed in a safe way with regulatory oversight, and only for a specific list of diseases. “It has to be within a legal context,” she says. “But to me, it’s a dream.”

In the meantime, the field looks set to keep transforming with the development of new technologies that are already creating healthy babies. Watch this space. 

Want to understand the current state of AI? Check out these charts.

<div data-chronoton-summary="

  • The US-China AI race is closer than you think: Chinese models from DeepSeek and Alibaba now trail American ones by razor-thin margins. Meanwhile, the US has more data centers and capital, while China leads in research publications and robotics.
  • AI benchmarks are badly broken: One popular math benchmark has a 42% error rate, and models can game tests by training on the answers. Strong test scores increasingly fail to predict how AI actually performs in the real world.
  • Jobs and anxiety are both rising: Software developer employment for workers aged 22–25 has dropped nearly 20% since 2022, with AI likely a factor. Globally, 59% of people think AI will do more good than harm—but 52% say it still makes them nervous.
  • Regulation is losing the race: The EU banned predictive policing AI, and US states passed a record 150 AI-related bills, but experts say lawmakers don’t yet understand the technology well enough to govern it effectively.

” data-chronoton-post-id=”1135675″ data-chronoton-expand-collapse=”1″ data-chronoton-analytics-enabled=”1″>

If you’re following AI news, you’re probably getting whiplash. AI is a gold rush. AI is a bubble. AI is taking your job. AI can’t even read a clock. The 2026 AI Index from Stanford University’s Institute for Human-Centered Artificial Intelligence, AI’s annual report card, comes out today and cuts through some of that noise. 

Despite predictions that AI development may hit a wall, the report says that the top models just keep getting better. People are adopting AI faster than they picked up the personal computer or the internet. AI companies are generating revenue faster than companies in any previous technology boom, but they’re also spending hundreds of billions of dollars on data centers and chips. The benchmarks designed to measure AI, the policies meant to govern it, and the job market are struggling to keep up. AI is sprinting, and the rest of us are trying to find our shoes.

All that speed comes at a cost. AI data centers around the world can now draw 29.6 gigawatts of power, enough to run the entire state of New York at peak demand. Annual water use from running OpenAI’s GPT-4o alone may exceed the drinking water needs of 12 million people. At the same time, the supply chain for chips is alarmingly fragile. The US hosts most of the world’s AI data centers, and one company in Taiwan, TSMC, fabricates almost every leading AI chip. 

The data reveals a technology evolving faster than we can manage. Here’s a look at some of the key points from this year’s report. 

The US and China are nearly tied

In a long, heated race with immense geopolitical stakes, the US and China are almost neck and neck on AI model performance, according to Arena, a community-driven ranking platform that allows users to compare the outputs of large language models on identical prompts. In early 2023, OpenAI had a lead with ChatGPT, but this gap narrowed in 2024 as Google and Anthropic released their own models. In February 2025, R1, an AI model built by the Chinese lab DeepSeek, briefly matched the top US model, ChatGPT. As of March 2026, Anthropic leads, trailed closely by xAI, Google, and OpenAI. Chinese models like DeepSeek and Alibaba lag only modestly. With the best AI models separated in the rankings by razor-thin margins, they’re now competing on cost, reliability, and real-world usefulness. 

Chart of the performance of top models on the Arena by select providers, showing the Arena score from May 2023 to Jan 2026 with the models all trending upward.  The scores are tightly packed by US based Anthropic, xAI, Google and OpenAI lead Alibaba, DeepSeek and Mistral (in that order.) Meta trails the pack.

The index notes that the US and China have different AI advantages. While the US has more powerful AI models, more capital, and an estimated 5,427 data centers (more than 10 times as many as any other country), China leads in AI research publications, patents, and robotics. 

As competition intensifies, companies like OpenAI, Anthropic, and Google no longer disclose their training code, parameter counts, or data-set sizes. “We don’t know a lot of things about predicting model behaviors,” says Yolanda Gil, a computer scientist at the University of Southern California who coauthored the report. This lack of transparency makes it difficult for independent researchers to study how to make AI models safer, she says.

AI models are advancing super fast

Despite predictions that development will plateau, AI models keep getting better and better. By some measures, they now meet or exceed the performance of human experts on tests that aim to measure PhD-level science, math, and language understanding. SWE-bench Verified, a software engineering benchmark for AI models, saw top scores jump from around 60% in 2024 to almost 100% in 2025. In 2025, an AI system produced a weather forecast on its own.  

“I am stunned that this technology continues to improve, and it’s just not plateauing in any way,” says Gil.

line chart of Select AI Index technical performance benchmarks vs human performance, showing that skills such as image classification, English language understanding, multitask language understanding, visual reasoning, medium level reading comprehension, multimodal understanding and reasoning have surpassed the human baseline at or before 2025, with autonomous software engineering, mathmatical reasoning and agent multimodal computer use trending towards meeting the human baseline by 2026.

However, AI still struggles in plenty of other areas. Because the models learn by processing enormous amounts of text and images rather than by experiencing the physical world, AI exhibits “jagged intelligence.” Robots are still in their early days and succeed in only 12% of household tasks. Self-driving cars are farther along: Waymos are now roaming across five US cities, and Baidu’s Apollo Go vehicles are shuttling riders around in China. AI is also expanding into professional domains like law and finance, but no model dominates the field yet. 

But the way we test AI is broken

These reports of progress should be taken with a grain of salt. The benchmarks designed to track AI progress are struggling to keep up as models quickly blow past their ceilings, the Stanford report says. Some are poorly constructed—a popular benchmark that tests a model’s math abilities has a 42% error rate. Others can be gamed: when models are trained on benchmark test data, for example, they can learn to score well without getting smarter. 

Because AI is rarely used the same way it’s tested, strong benchmark performance doesn’t always translate to real-world performance. And for complex, interactive technologies such as AI agents and robots, benchmarks barely exist yet. 

AI companies are also sharing less about how their models are trained, and independent testing sometimes tells a different story from what they report. “A lot of companies are not releasing how their models do in certain benchmarks, particularly the responsible-AI benchmarks,” says Gil. “The absence of how your model is doing on a benchmark maybe says something.” 

AI is starting to affect jobs

Within three years of going mainstream, AI is now used by more than half of people around the world, a rate of adoption faster than the personal computer or the internet. An estimated 88% of organizations now use AI, and four in five university students use it. 

It’s early days for deployment, and AI’s impact on jobs is hard to measure. Still, some studies suggest AI is beginning to affect young workers in certain professions. According to a 2025 study by economists at Stanford, employment for software developers aged 22 to 25 has fallen nearly 20% since 2022. The decline might not be pinned on AI alone, as broader macroeconomic conditions could be to blame, but AI appears to be playing a part.

two line charts showing the normalized headcount trends by age group from 2021 through 2025. On the left for software developers the early career (age 22-25) cohort drops rapidly after a peak in September 2022, with other ages still rising albeit less steeply.  On the right, customer support agents see a similar trend, although the decline for the early career group is less steep than for software developers.

Employers say that hiring may continue to tighten. According to a 2025 survey conducted by McKinsey & Company, a third of organizations expect AI to shrink their workforce in the coming year, particularly in service and supply chain operations and software engineering. AI is boosting productivity by 14% in customer service and 26% in software development, according to research cited by the index, but such gains are not seen in tasks requiring more judgment. Overall, it’s still too early to understand the bigger economic impact of AI. 

People have complicated feelings about AI 

Around the world, people feel both optimistic and anxious about AI: 59% of people think that it will provide more benefits than drawbacks, while 52% say that it makes them nervous, according to an Ipsos survey cited in the index. 

Notably, experts and the public see the future of AI very differently, according to a Pew survey. The biggest gap is around the future of work: While 73% of experts think that AI will have a positive impact on how people do their jobs, only 23% of the American public thinks so. Experts are also more optimistic than the public about AI’s impact on education and medical care, but they agree that AI will hurt elections and personal relationships.

Bar chart of US perceptions of AI's societal impact contrasting US adults with AI experts, with the percentage of AI experts saying that AI will have a positive impact in the next 20 years is 2-3 times higher than the US adults.  The most optimistic AI experts are in the field of medical care with 84% predicting a positive outcome (versus 44% of US adults.) The greatest difference is for jobs with experts polling at 73% and US adults  polling at 23%.  Both groups have a similar (11% for experts and 9% of adults.) expectation for a positive outcome for AI in elections.

Among all countries surveyed, Americans trust their government least to regulate AI appropriately, according to another Ipsos survey. More Americans worry federal AI regulation won’t go far enough than worry it will go too far. 

Governments are struggling to regulate AI

Governments around the world are struggling to regulate AI, but there were some minor successes last year. The EU AI Act’s first prohibitions, which ban the use of AI in predictive policing and emotion recognition, took effect. Japan, South Korea, and Italy also passed national AI laws. Meanwhile, the US federal government moved toward deregulation, with President Trump issuing an executive order seeking to handcuff states from regulating AI. 

Despite this federal action, state legislatures in the US passed a record 150 AI-related bills. California enacted landmark legislation, including SB 53, which mandates safety disclosures and whistleblower protections for developers of AI models. New York passed the RAISE Act, requiring AI companies to publish safety protocols and report critical safety incidents.

line chart showing the number of AI-related bills passed into law by all US states from 2016-2025, which increases sharply in 2023 and peaks with 150 bills in 2025.

But for all the legislative activity, Gil says, regulation is running behind the technology because we don’t really understand how it works. “Governments are cautious to regulate AI because … we don’t understand many things very well,” she says. “We don’t have a good handle on those systems.”

Desalination plants in the Middle East are increasingly vulnerable

<div data-chronoton-summary="

  • Water as a weapon: Desalination plants supplying drinking water to millions across the Middle East have become targets in the escalating US-Iran conflict, with plants in Iran, Bahrain, and Kuwait already reporting damage.
  • Gulf states are most at risk: While Iran gets just 3% of its municipal fresh water from desalination, Bahrain, Qatar, and Kuwait depend on it for over 90% of their drinking water—making them far more exposed to attacks.
  • Bigger plants mean bigger consequences: The average desalination facility is now ten times larger than it was 15 years ago. Taking one offline could impact the water supplies of many people in the area.
  • The danger doesn’t end with the war: Climate change, oil spills, and algae blooms pose growing threats to these facilities—and experts warn the conflict may teach future actors just how effectively water infrastructure can be weaponized.

” data-chronoton-post-id=”1135235″ data-chronoton-expand-collapse=”1″ data-chronoton-analytics-enabled=”1″>

MIT Technology Review Explains: Let our writers untangle the complex, messy world of technology to help you understand what’s coming next. You can read more from the series here.

As the conflict in Iran has escalated, a crucial resource is under fire: the desalination technology that supplies water across much of the region.

In early March, Iran’s foreign minister accused the US of attacking a desalination plant on Qeshm Island in the Strait of Hormuz and disrupting the water supply to nearly 30 villages. (The US denied responsibility.) In the weeks since, both Bahrain and Kuwait have reported damage to desalination plants and blamed Iran, though Iran also denied responsibility.

In late March, President Donald Trump threatened the destruction of “possibly all desalinization plants” in Iran if the Strait of Hormuz was not reopened. Since then, he’s escalated his threats against Iran, warning of plans to attack other crucial civilian infrastructure like power plants and bridges.

Countries in the Middle East, particularly the Gulf states, rely on the technology to turn salt water into fresh water for farming, industry, and—crucially—drinking. The mounting attacks and threats to date highlight just how vital the industry is to the region—a situation made even more precarious by rising temperatures and extreme weather driven by climate change.

Right now, 83% of the Middle East is under extremely high water stress, says Liz Saccoccia, a water security associate at the World Resources Institute. Future projections suggest that’s going to increase to about 100% by 2050, she adds: “This is a continuing trend, and it’s getting worse, not better.”

Here’s a look at desalination technology in the Middle East and what wartime threats to the critical infrastructure could mean for people in the region. 

A vital resource

Desalination technology has helped provide water supplies in the Middle East since the early 20th century and became widespread in the 1960s and 1970s.

There are two major categories of desalination plants. Thermal plants use heat to evaporate water, leaving salt and other impurities behind. The vapor can then be condensed into usable fresh water. The alternative is membrane-based technology like reverse osmosis, which pushes water through membranes that have tiny pores—so small that salt can’t get through.

Early desalination plants in the Middle East were the first type, burning fossil fuels to evaporate water, leaving the salt behind. This technique is incredibly energy-intensive, and over time, processes that rely on filters became the dominant choice.

Membrane technologies have made up essentially all new desalination capacity in recent years; the last major thermal plant built in the Gulf came online in 2018. Many reverse osmosis plants still rely on fossil fuels, but they’re more efficient. Since then, membrane technologies have added more than 15 million cubic meters of daily capacity—enough to supply water to millions of people.

Capacity has expanded quickly in recent years; between 2006 and 2024, countries across the Middle East collectively spent over $50 billion building and upgrading desalination facilities, and nearly that much operating them.

Today, there are nearly 5,000 desalination plants operational across the Middle East.

And looking ahead, growth is continuing. Between 2024 and 2028, daily capacity is expected to grow from about 29 million cubic meters to 41 million cubic meters.

Uneven vulnerabilities

Some countries rely on the technology more than others. Iran, for example, uses desalination for about 3% of its municipal fresh water. The country has access to groundwater and some surface water, including rivers, though these resources are being stretched thin by agriculture and extreme drought.

Other nations in the region, particularly the Gulf countries (Bahrain, Qatar, Kuwait, the United Arab Emirates, Saudi Arabia, and Oman), have much more limited water resources and rely heavily on desalination. Across these six nations, all but the UAE get more than half their drinking water from desalination, and for Bahrain, Qatar, and Kuwait the figure is more than 90%.

“The Gulf countries are much, much more vulnerable to attacks on their desalination plants than Iran is,” says David Michel, a senior associate in the global food and water security program at the Center for Strategic and International Studies.

There are thousands of desalination facilities across the region, so the system wouldn’t collapse if a small number were taken offline, Michel says. However, in recent years there’s been a trend toward larger, more centralized plants.

The average desalination plant is about 10 times larger than it was 15 years ago, according to data from the International Energy Agency. The largest desalination plants today can produce 1 million cubic meters of water daily, enough for hundreds of thousands of people. Taking one or more of these massive facilities offline could have a significant effect on the system, Michel says.

Escalating threats

Desalination facilities are quite linear, meaning there are multiple steps and pieces of equipment that work in sequence—and the failure of a component in that chain can take an entire facility down. Attacks on water inlets, transportation networks, and power supplies can also disrupt the system, Michel says. 

During the Gulf War in 1991, Iraqi forces pumped oil into the gulf, contaminating the water and shutting down desalination plants in Kuwait

The facilities are also generally located close to other targets in this conflict. Desalination is incredibly energy intensive, so about three-quarters of facilities in the region are next to power plants. Trump has repeatedly threatened power plants in Iran. In response, Iran’s military has said that if civilian targets are hit, the country will respond with strikes that are “much more devastating and widespread.” Other governments and organizations, including the United Nations, the European Union, and the Red Cross, have broadly condemned threats to infrastructure as illegal. 

But war isn’t the only danger facing these plants, even if it is the most immediate. Some studies have suggested that global warming could strengthen cyclones in the region, and these extreme weather events could force shutdowns or damage equipment.

Water pollution could also cause shutdowns. Oil spills, whether accidental or intentional, as in the case of the Gulf War, can  wreak havoc. And in 2009, a red algae bloom closed desalination plants in Oman and the United Arab Emirates for weeks. The algae fouled membranes and blocked the plants from being able to take water in from the Persian Gulf and the Gulf of Oman.

Desalination facilities could become more resilient to threats in the future, and they may need to as their importance continues to grow. 

There’s increasing interest in running desalination facilities at least partially on solar power, which could help reduce dependence on the oil that powers most facilities today. The Hassyan seawater desalination project in the UAE, currently under construction, would be the largest reverse osmosis plant in the world to operate solely with renewable energy. 

Another way to increase resilience is for countries to build up more strategic water storage to meet demand. Qatar recently issued new policies that aim to improve management and storage of desalinated water, for example. Countries could also work together to invest in shared infrastructure and policies that help strengthen the water supply through the region. 

Preparedness, resilience, and cooperation will be key for the Middle East broadly as critical infrastructure, including the water supply, is increasingly under threat. 

“The longer the conflict goes on, the more likely we’ll see significant water infrastructure damage,” says Ginger Matchett, an assistant director at the Atlantic Council. “What worries me is that after this war ends, some of the lessons will show how water can be weaponized more strategically than previously imagined.”